PCWG4 vs PCWG3: Advanced Prostate Cancer Terminology Overhaul

/in /by

The Prostate Cancer Working Group 4 (PCWG4), published in February 2026, introduces patient-centric updates to advanced prostate cancer trial design, shifting from PCWG3’s clinical state model to a therapeutic indication framework. PCWG4 replaces outdated terms like “castration-resistant prostate cancer” (CRPC), “non-metastatic castration-resistant prostate cancer” (nmCRPC), “metastatic castration-resistant prostate cancer” (mCRPC), “hormone-sensitive prostate cancer” (HSPC), and […]

Read more

WOLVERINE Study Shows The Benefits of Metastases Directed Therapy

/in /by

The WOLVERINE study is a major analysis combining patient data from seven phase 2 trials, published in The Lancet Oncology. It looked at 574 men with oligometastatic prostate cancer (meaning up to five spots of cancer spread), mostly to bones or lymph nodes. Six of those trials (472 men) directly compared adding metastasis-directed therapy (MDT) […]

Read more

Dr. Sartor Explains the ARTISAN Trial

/in /by

In a recent presentation, Dr. Oliver Sartor highlighted Lead-212 (Pb-212) as a promising next step in precision radioligand therapy for metastatic castration-resistant prostate cancer. Developed by the same Oslo-based team that introduced Radium-223, Lead-212 is being studied in the ARTISAN (AB001) trial and represents a significant evolution in alpha-emitting radiopharmaceuticals. Its defining features are a […]

Read more

One year (almost) of ProstateWarriors.com and where are we?

/in /by
Read more